{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/non-alcoholic-fatty-liver-disease-nafld/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"66b72646-5ad1-5d7a-91e0-65e06d4da026","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 60cf43c4-9c27-45c0-bc41-3eb7c51704f4 --><h2>Prevalence</h2><!-- end field 60cf43c4-9c27-45c0-bc41-3eb7c51704f4 -->","summary":"","htmlStringContent":"<!-- begin item ba296a7c-8a6d-4330-a76c-252aeff88715 --><!-- begin field abf8a9fc-164d-40f0-968b-633703ba2213 --><ul><li><strong>The reported prevalence of non-alcoholic fatty liver disease (NAFLD) varies widely depending on the population studied and the definition of NAFLD used </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Chalasani et al, 2012</a>].<ul><li>Prevalence increases with increasing age, and is highest in males aged 40–65 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Ratziu et al, 2010</a>].</li><li>The prevalence of NAFLD has doubled over the past 20 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2014</a>].</li></ul></li><li>In the UK, a retrospective study reported an incidence rate of 29 cases of NAFLD per 100,000 person-years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Whalley et al, 2007</a>].</li><li>In Europe, the prevalence of NAFLD in the general population assessed by ultrasound scan is estimated to be 20–30%, and in apparently healthy, living liver donors, the prevalence of non-alcoholic steatohepatitis (NASH) ranges from 3–16% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">World Gastroenterology Organisation, 2012</a>].<ul><li>A review article (study population not specified) states that about 10–30% of people with NAFLD develop NASH, and about 25–40% of people with NASH will develop progressive liver fibrosis, resulting in cirrhosis in 20–30% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2014</a>].</li><li>A further review article states that the yearly cumulative incidence of hepatocellular carcinoma (HCC) is 2.6% in people with NASH cirrhosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Dyson et al, 2015</a>].</li><li>Studies in tertiary referral centres have shown a prevalence of NASH of 43–55% in people with elevated liver function tests (specifically, aminotransferases), and as high as 49% in people with morbid obesity. The prevalence of cirrhosis in people with NASH at diagnosis is 10–15% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Ratziu et al, 2010</a>].</li><li>NASH is thought to be the cause of 30–75% of cases of advanced liver disease where no specific cause has been identified (often termed 'cryptogenic cirrhosis') [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Anstee et al, 2011</a>].</li></ul></li><li>Worldwide, a systematic review of 85 studies (n = 8,515,431) estimated the pooled overall global prevalence of NAFLD diagnosed by imaging to be 25.24% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/references/\">Younossi, 2016</a>].<ul><li>The highest prevalence was reported in South America and the Middle East, and the lowest rate was reported in Africa.</li></ul></li></ul><!-- end field abf8a9fc-164d-40f0-968b-633703ba2213 --><!-- end item ba296a7c-8a6d-4330-a76c-252aeff88715 -->","topic":{"id":"abeafb29-55b4-564c-a734-190ce99b5488","topicId":"284bcb15-d9e5-4fa5-97c5-b12061b64d8d","topicName":"Non-alcoholic fatty liver disease (NAFLD)","slug":"non-alcoholic-fatty-liver-disease-nafld","lastRevised":"Last revised in October 2016","chapters":[{"id":"d0fc610b-a161-5d27-aff1-910d3e6bd6af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"748ff87f-6f43-5b88-826b-8a67516fdf5f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a580b3e-3e5e-50fe-bbe8-63c6a475223b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cfdf5ea1-068e-544d-a066-a9e0b5007c65","slug":"changes","fullItemName":"Changes"},{"id":"2d1f70a5-e0ca-56d6-af3c-40bcced1ff70","slug":"update","fullItemName":"Update"}]},{"id":"f6da1f95-da2b-55bd-8bd1-82a26c6e49f3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2df5bf15-3a0c-550d-b1ae-49c13b980bd2","slug":"goals","fullItemName":"Goals"},{"id":"899d29ba-a633-5852-b88b-1e12f2e583a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"98a2b07c-cb2b-5bf6-8758-a1ffcef6d2b8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"567377f9-5d4b-58d2-961d-c67f47aa67b3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"20b1d2c6-1aab-5c3c-8560-98f485589680","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bde5c853-d1bc-5612-b254-6de06cef5bca","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"271f684c-2115-5009-831e-20aa4e06a952","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9d30a3cc-c4cb-5049-8a58-68e8628c259e","slug":"definition","fullItemName":"Definition"},{"id":"66b72646-5ad1-5d7a-91e0-65e06d4da026","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a5c1fa8-bae7-517a-beac-7470da445796","slug":"causes","fullItemName":"Causes"},{"id":"c1592142-fe7a-537c-8d46-2d3836ae5625","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5f220e0c-e0b7-5332-a19d-50b80b98f34e","slug":"complications","fullItemName":"Complications"},{"id":"ad47e9ed-f83a-51bb-874e-85ea1a9756c3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2755df5f-b687-58d9-9f7c-96df41230049","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9faeeb6d-9870-5bd7-bfd4-35cfd840ff5b","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e0b64459-7125-5764-b029-3c2c2d770254","slug":"assessment","fullItemName":"Assessment"}]},{"id":"df1d3ccc-4b69-5415-bf4d-b81e66c90d85","fullItemName":"Management","slug":"management","subChapters":[{"id":"92480bd7-0484-5fe9-a7bf-d6797adb368e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c7f01d1-e8b6-5b31-8c34-b4e6ecd555e8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"00b0d6bf-28e1-5673-b966-4dd5bbb035cc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e3a16505-5916-56fe-b828-251f23afd363","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"753add0e-0bf6-59e4-b5a7-e46df0904d4c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6942026-4d74-5fbd-bb79-1aae8f3b4576","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c2dffddc-29cb-5918-ad31-69cdb772fa22","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"47354e90-5f65-5a83-b670-29798add860f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c12b3b71-cdfd-532e-a293-8cd38e7b7b1e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"271f684c-2115-5009-831e-20aa4e06a952","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}